As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

Daratumumab, a human IgG1κ monoclonal antibody ... During the donor search, the recipient received four cycles of hypomethylating chemotherapy. A matched, unrelated donor was identified with ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with ...

President Trump touted a new Executive Order that would more closely align drug prices in the US with those sold in Europe ...

fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] Technology appraisal guidance TBC Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer ...

After more than 7 years of follow-up, daratumumab (Darzalex ... 18 years or older with newly diagnosed multiple myeloma who were ineligible for high-dose chemotherapy with autologous stem cell ...

New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery, and radiation for some forms of cancer. Nearly 80% of patients who suffered from ...

New cancer research pioneered by Memorial Sloan Kettering points to a strong alternative to chemotherapy, surgery and radiation for some forms of cancer. Nearly 80% of patients who suffered from a ...

In early April 2025, the EC approved an extended indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous formulation for newly diagnosed multiple myeloma in adults. Give your ...